新股暗盤 | 兆科眼科-B(6622.HK)暗盤段跌4.7%
格隆匯4月28日丨兆科眼科-B(6622.HK)暗盤段持續走低,現報16港元,較發行價16.8港元跌4.7%。公司是由李氏大藥廠分拆上市,全球發售約1.236億股,其中香港發售4942.7萬股,國際發售7414.05萬股,每手500股,一手中籤率25%,香港公開發售獲56倍認購,淨籌19.416億港元。新加坡政府投資公司、高領等多家基石投資者已認購2546.1萬股發售股份,相當於公司緊隨全球發售完成後已發行股份總數約4.76%。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.